Celgene

CELG NASDAQ
94.74
+1.43
+1.53%
After Hours: 94.87 +0.13 +0.14% 18:32 08/16 EDT
Open
93.92
Prev Close
93.31
High
94.85
Low
93.25
Volume
2.68M
Avg Vol (3M)
4.30M
52 Week High
98.97
52 Week Low
58.59
% Turnover
0.38%
Market Cap
67.15B
1D
5D
1M
3M
1Y
5Y

Related

Webull offers Celgene CELG stock price, real time market quotes, professional analyst ratings, and in-depth charts, You can share investing ideas in community to communicate with others and learn trading skills.

Company Profile

Celgene Corporation is an integrated global biopharmaceutical company. The Company, together with its subsidiaries, is engaged in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases through solutions in protein homeostasis, immuno-oncology, epigenetics, immunology and neuro-inflammation. Its commercial-stage products include REVLIMID (lenalidomide), POMALYST/IMNOVID (pomalidomide), OTEZLA (apremilast), ABRAXANE (paclitaxel albumin-bound particles for injectable suspension), VIDAZA, azacitidine for injection (generic version of VIDAZA) and THALOMID (thalidomide). Its clinical trial activity includes trials across the disease areas of hematology, solid tumors, and inflammation and immunology. The Company also markets ISTODAX, which is an epigenetic modifier. The Company is also evaluating AG-221 (enasidenib) in combination with VIDAZA in newly diagnosed acute myeloid leukemia with isocitrate dehydrogenase-2 mutations.
MORE >

Recently

Name
Price
%Change